» Authors » Stephen H Zinner

Stephen H Zinner

Explore the profile of Stephen H Zinner including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 64
Citations 479
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Strukova E, Portnoy Y, Golikova M, Zinner S
Pharmaceuticals (Basel) . 2025 Jan; 17(12. PMID: 39770525
A potential strategy to maintain the efficacy of carbapenems against carbapenemase-producing (CPKP) is their combination with carbapenemase inhibitors. To address these issues, the effectiveness of a novel combination of meropenem...
2.
Alieva K, Golikova M, Zinner S
J Antimicrob Chemother . 2024 Aug; 79(10):2698-2707. PMID: 39178131
Objectives: Pharmacodynamic parameters evaluated under conditions that simulate an infection site volume and microbial load might reveal hidden risks of resistance selection and subsequent treatment failure. The study aimed to...
3.
Golikova M, Alieva K, Strukova E, Kondratieva D, Petrova N, Petrova M, et al.
Antibiotics (Basel) . 2023 Dec; 12(12). PMID: 38136751
Resistance to carbapenems has become a problem due to (), harboring carbapenemases. Among them, there are isolates that are recognized as carbapenem-susceptible; however, these carbapenemase-producing strains with low meropenem minimal...
4.
Strukova E, Golikova M, Dovzhenko S, Kobrin M, Zinner S
Antibiotics (Basel) . 2023 Dec; 12(12). PMID: 38136739
The emergence of bacteria resistant to beta-lactam/beta-lactamase inhibitor combinations is insufficiently studied, wherein the role of the inoculum effect (IE) in decreased efficacy is unclear. To address these issues, 5-day...
5.
Alieva K, Golikova M, Dovzhenko S, Kobrin M, Strukova E, Ageevets V, et al.
PLoS One . 2023 Aug; 18(8):e0288660. PMID: 37540701
OXA-48 carbapenemases are frequently expressed by Klebsiella pneumoniae clinical isolates; they decrease the effectiveness of carbapenem therapy, particularly with meropenem. Among these isolates, meropenem-susceptible carbapenemase-producers may show decreased meropenem effectiveness....
6.
Alieva K, Golikova M, Kuznetsova A, Zinner S
Antibiotics (Basel) . 2023 Jul; 12(7). PMID: 37508266
The development and implementation of diagnostic methods that allow rapid assessment of antibiotic activity against pathogenic microorganisms is an important step towards antibiotic therapy optimization and increase in the likelihood...
7.
Golikova M, Strukova E, Alieva K, Ageevets V, Avdeeva A, Sulian O, et al.
Antibiotics (Basel) . 2023 May; 12(5). PMID: 37237775
The minimal inhibitory concentration (MIC) is conventionally used to define in vitro levels of susceptibility or resistance of a specific bacterial strain to an antibiotic and to predict its clinical...
8.
Golikova M, Alieva K, Filimonova A, Ageevets V, Sulian O, Avdeeva A, et al.
Biomedicines . 2022 Jun; 10(6). PMID: 35740475
The inoculum effect (IE) is a well-known phenomenon with beta-lactams. At the same time, the IE has not been extensively studied with carbapenem/carbapenemase inhibitor combinations. The antibiotic-to-inhibitor concentration ratio used...
9.
Filimonova A, Golikova M, Strukova E, Portnoy Y, Kuznetsova A, Zinner S
Antibiotics (Basel) . 2021 Dec; 10(12). PMID: 34943731
Traditionally, the antibacterial activity of β-lactam antibiotics in the presence of β-lactamase inhibitors is determined at the fixed inhibitor concentration. This traditional approach does not consider the ratio of antibiotic-to-inhibitor...
10.
Golikova M, Strukova E, Portnoy Y, Zinner S, Firsov A
Antibiotics (Basel) . 2021 Oct; 10(10). PMID: 34680729
To explore whether combined treatments with daptomycin and gentamicin can prevent the development of resistance, and whether the possible restriction is associated with changes in antibiotic mutant prevention concentrations (MPCs),...